Currently approved post-exposure rabies prophylaxis regimens.

H. Wilde,S. Wacharapluesadee,T. Hemachudha

DOI: https://doi.org/10.1016/j.tmaid.2012.03.004

IF: 20.441

2012-05-01

Travel Medicine and Infectious Disease

Abstract:

What problem does this paper attempt to address?

To Cut is to Cure: The Surgeon's Role in Improving Value

J. Jopling,Clifford C. Sheckter,B. James

DOI: https://doi.org/10.1097/SLA.0000000000002596

IF: 13.787

2017-11-01

Annals of Surgery

Abstract:SURGEONS WILL INCREASINGLY BEAR FINANCIAL RISK WITH NEW PAYMENT MODELSValue-based reimbursement is supplanting traditional fee-for-service payment. Forward thinking payers, providers, and patients are redesigning care delivery to maximize patient experience and population-level health at an affordab
Effect of colostomy on experimentally produced neoplasms of the colon of the rat

A. Navarrete,H. Spjut

DOI: https://doi.org/10.1002/1097-0142(196709)20:9<1466::AID-CNCR2820200913>3.0.CO;2-D

IF: 6.9209

1967-09-01

Cancer

Abstract:As a means of determining the effect of the fecal stream in the pathogenesis of experimentally produced colonic tumors in Wistar strain rats, simple colostomies were performed in the left colon of 57 female rats at approximately 4 cm above the anus. Fifty‐four rats received daily subcutaneous injections, 5 days per week, of the carcinogen 3:2'dimethyl‐4‐aminodiphenyl at a dosage of 2 mg/day/100 Gm body weight. Of the 54 rats, 17 (31.4%) developed either hyperplasia, adenomatous polyps or carcinoma of the large bowel proximal to the colostomy site. None of the 54 rats developed any lesion distal to the colostomy. None of the three control rats with colostomies developed any kind of tumor. Of the colonic lesions that developed, 12 were hyperplasias, 12 were adenomatous polyps and four were carcinomas. All hyperplasia developed at colostomy edge. Diversion of the fecal stream prevents development of colonic neoplasms in Wistar rats in this experimental situation.
Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Kossara Drenovska,Elia Valeva,Martin Shahid,Snejina Vassileva

DOI: https://doi.org/10.3389/fmed.2023.1148660

IF: 3.9

2023-04-03

Frontiers in Medicine

Abstract:Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflammation may cause pathological changes to the basement membrane zone, thus inducing autoimmunity against BP antigens through cross reactivity and “epitope spreading.” The coexistence of BP and psoriasis poses challenging therapeutic dilemmas related to the incompatibility of their standard treatments. Considering the probable common immunologic mechanisms in the pathogenesis of these inflammatory skin disorders, a suitable treatment regimen should be applied for their parallel control. We report three patients, who developed BP in the course of preceding long-lasting psoriasis. Secukinumab was administered as first-line treatment with promising therapeutic effect for both skin disorders and long-term disease control in two of the cases. In the third case, parallel disease control was initially achieved with methotrexate. A few years later, secukinumab was used for the treatment of a relapse of both dermatoses but worsening of BP was observed and methotrexate was reintroduced. Our experience on the therapeutic potential of secukinumab in BP is supported by the data in the literature. Recently, it was demonstrated that the proinflammatory cytokine IL17A has a functional role in the process of skin inflammation in BP, similarly to psoriasis. IL17A inhibition has emerged as a promising therapeutic strategy in patients with extensive or refractory BP but paradoxical development of BP after secukinumab treatment for psoriasis has also been described. This controversy emphasizes the need for further investigation into the development of optimal treatment strategies and recommendations.

medicine, general & internal
Malignancies in bullous pemphigoid: A controversial association

Riccardo Balestri,Michela Magnano,Michelangelo La Placa,Annalisa Patrizi,Luisa Angileri,Vera Tengattini,Federico Bardazzi

DOI: https://doi.org/10.1111/1346-8138.13079

Abstract:Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disorder that has been reported to be associated with malignancies. Some authors described several cases of pemphigoid associated with malignancies (PAM); however, the evidence of this correlation still remains controversial. Several theories have been postulated to explain the relationship between malignant neoplasms and BP; the main theory suggests that antibodies directed against tumor-specific antigens of malignant cells may cross-react with antigens (like BP antigens) in the basement membrane zone leading to the formation of blisters. We performed an extensive review of the English published work focusing on the epidemiology, the pathogenetic theories and the clinical and histological aspects of the disease. We identified 40 cases of PAM: of these, seven cases were associated with hematological malignancies and 33 with solid tumors. Physicians should be aware of the existence of PAM and we suggest an oncological screening in early-onset pemphigoid, in patients with a former oncological history, in those with signs and symptoms that could be related to a neoplasm and in BP refractory to common immunosuppressive therapy.
Effects of a candidate antifouling compound (medetomidine) on pheromone induced mate search in the amphipod Corophium volutator.

Anna-Sara Krång,M. Dahlström

DOI: https://doi.org/10.1016/J.MARPOLBUL.2006.09.015

IF: 5.8

2006-12-01

Marine Pollution Bulletin

Abstract:
Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

Francesco Moro,Feliciana Mariotti,Anna Pira,Naomi De Luca,Biagio Didona,Gianluca Pagnanelli,Giovanni Di Zenzo

DOI: https://doi.org/10.3389/fmed.2022.1055045

2022-12-08

Abstract:Background: Bullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal junction, BP180 and BP230. A large number of autoimmune diseases are reported in the literature as BP comorbidities, such as multiple sclerosis, but only a few cases are in association with scleroderma and none in association with both. Case presentation: We present the case of a 68-year-old woman affected by multiple sclerosis and scleroderma who developed severe bullous pemphigoid with a bullous pemphigoid disease area index of 60 and high titers of anti-BP180 and anti-BP230 autoantibodies by enzyme-linked immunosorbent assays. After 2 months of therapy with both intravenous and oral corticosteroids, the active lesions of bullous pemphigoid were remitted with no relapse. Conclusion: Autoimmune diseases affecting the skin or organs where BP180 and BP230 are present could trigger an immune response to these antigens through an epitope-spreading phenomenon and, over the years, induce bullous pemphigoid onset.
The effect of platinum derivatives on interfacial properties of DNA.

D. Kasparova,O. Vrána,V. Kleinwächter,V. Brabec

DOI: https://doi.org/10.1016/0301-4622(87)80089-3

IF: 3.628

1987-12-01

Biophysical Chemistry

Abstract:
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Meropi Karakioulaki,Kilian Eyerich,Aikaterini Patsatsi

DOI: https://doi.org/10.1007/s40257-023-00832-1

Abstract:Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Victoria P. Werth,Dédée F. Murrell,Pascal Joly,Renata Heck,Jamie M. Orengo,Marius Ardeleanu,Verena Hultsch

DOI: https://doi.org/10.1007/s12325-024-02992-w

2024-11-11

Advances in Therapy

Abstract:Bullous pemphigoid (BP) is an autoimmune blistering disease that most often affects elderly individuals and has a significant negative impact on quality of life. The disease is characterized primarily by autoantibodies to hemidesmosomal proteins BP180 and/or BP230, and an inflammatory reaction with notable features of type 2 inflammation, including elevated serum IgE, increased numbers of eosinophils in lesions and peripheral blood, and elevated expression of type 2 cytokines and chemokines in skin lesions. In this review, we present what is known about BP pathophysiology, including the role of type 2 inflammation, and discuss how findings from studies of biologics targeting type 2 immune mediators have helped to clarify the biological mechanisms driving BP pathophysiology. Future studies of these targeted therapies and others in development will help to further elucidate the mechanisms underlying BP pathophysiology and potentially provide better treatment options for patients.

pharmacology & pharmacy,medicine, research & experimental
Neurological and psychiatric associations in bullous pemphigoid-more than skin deep?

Anna‐Kaisa Försti,Laura Huilaja,Enno Schmidt,Kaisa Tasanen,Anna-Kaisa Försti

DOI: https://doi.org/10.1111/exd.13401

2017-09-24

Experimental Dermatology

Abstract:In elderly patients, bullous pemphigoid (BP) is associated with several comorbidities; the strongest association occurs between BP and neurological diseases. Different types of dementia, Parkinson's disease, cerebrovascular disorders and epilepsy all have a significant association with BP, but patients with multiple sclerosis have the highest risk of BP. An existing neurological disorder appears to increase the risk for subsequent BP, but an increased risk for developing some neurological diseases has also been reported following BP diagnosis. BP seems to be associated with several psychiatric diseases such as schizophrenia, uni- and bipolar disorder, schizotypal and delusional disorders, and personality disorders, but the risk ratios are usually lower than with neurological diseases. In addition to the skin, the BP autoantigens BP180 and BP230 are expressed in the central nervous system. This finding together with the strong epidemiological association between neurological disorders and BP has led to an assumption that neurodegeneration or neuroinflammation could lead to a cross-reactive immunoresponse between neural and cutaneous antigens and the failure of self-tolerance. A subpopulation of patients with Alzheimer's disease or Parkinson's disease have circulating IgG autoantibodies against BP180, but currently their significance for the development of BP is unclear, because these antineural BP180 antibodies neither bind to the cutaneous basement membrane nor cause BP-like symptoms. Further studies analysing large and well-characterized populations of neurological and psychiatric patients are required to understand better the role of autoimmunization against neural BP autoantigens in the pathogenesis of BP.

dermatology
Prevalence and genotypes of Giardia duodenalis in 1-2 year old dairy cattle.

J. Trout,M. Santín,E. Greiner,R. Fayer

DOI: https://doi.org/10.1016/J.VETPAR.2006.03.025

IF: 2.821

2006-09-10

Veterinary Parasitology

Abstract:
Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report

Jing-Hua Liu,Qian Gao,Wen-Yi Ma,Zi-Lin Cheng,Na-Na Luo,Ping-Sheng Hao

DOI: https://doi.org/10.2147/CCID.S415019

2023-06-20

Abstract:Psoriasis is an immune-mediated chronic inflammatory disease that can be combined with complications such as diabetes, cardiovascular disease, obesity, and kidney disease. The comorbidity of psoriasis with autoimmune bullous diseases (AIBD) has been reported previously in several cases, the most frequent of which is bullous pemphigoid (BP). The underlying mechanisms of psoriasis with BP are not clear and there are no uniform treatment criteria. Based on previous case reports, the coexistence of psoriasis and BP may be related to inflammatory activity, medications, phototherapy, and infection. We report a case of a psoriasis patient who developed BP after taking Chinese herbal compounds and was successfully treated with dupilumab, which is the first reported case of applying dupilumab to treat psoriasis with BP comorbidities.
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

Belen de Nicolas-Ruanes,Asuncion Ballester-Martinez,Emilio Garcia-Mouronte,Emilio Berna-Rico,Carlos Azcarraga-Llobet,Montserrat Fernandez-Guarino

DOI: https://doi.org/10.3390/ijms242316786

2023-11-26

Abstract:Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane zone. This leads to the activation of complement-dependent and independent pathways, resulting in proteolytic cleavage at the dermoepidermal junction and an eosinophilic inflammatory response. While numerous drugs have been associated with BP in the literature, causality and pathogenic mechanisms remain elusive in most cases. Dipeptidyl peptidase 4 inhibitors (DPP4i), in particular, are the most frequently reported drugs related to BP and, therefore, have been extensively investigated. They can potentially trigger BP through the impaired proteolytic degradation of BP180, combined with immune dysregulation. DPP4i-associated BP can be categorized into true drug-induced BP and drug-triggered BP, with the latter resembling classic BP. Antineoplastic immunotherapy is increasingly associated with BP, with both B and T cells involved. Other drugs, including biologics, diuretics and cardiovascular and neuropsychiatric agents, present weaker evidence and poorly understood pathogenic mechanisms. Further research is needed due to the growing incidence of BP and the increasing identification of new potential triggers.
Intraorbital arteriovenous fistula secondary to penetrating injury.

B. Yazıcı,Z. Yazıcı,C. Erdoğan,J. Rootman

Ophthalmic Plastic and Reconstructive Surgery

Abstract:PURPOSE : To describe the clinical and radiologic features and management of an intraorbital arteriovenous fistula secondary to penetrating injury. METHOD : Interventional case report and literature review. RESULTS : We describe a 13-year-old girl with a history of penetrating orbital injury who presented with proptosis, eyelid hyperemia, and orbital venous congestion. Computed tomography showed a large foreign body in the superiormedial orbit and an enlarged superior ophthalmic vein (SOV). Doppler ultrasonography revealed arterialized flow in the SOV. Removal of the foreign body did not alter the orbital symptoms. Carotid angiography disclosed a fistula between the ophthalmic artery and the SOV. The patient underwent an attempted coil embolization of the fistula through the femoral vein, which was unsuccessful, but she developed profound thrombosis of the SOV, which propagated through the orbital venous system. Although orbital venous congestive symptoms were acutely exacerbated, they regressed spontaneously within 1 month. The patient was followed for 23 months without recurrence. CONCLUSIONS : Penetrating injury of the orbital apex may lead to the formation of an arteriovenous fistula, transvenous embolization of which may be complicated by thrombosis of the SOV. In our case, this unintentional result facilitated the resolution of the fistula.
Wound keratins in the regenerating epidermis of lizard suggest that the wound reaction is similar in the tail and limb.

L. Alibardi,M. Toni

DOI: https://doi.org/10.1002/JEZ.A.213

2005-10-01

Journal of Experimental Zoology Part A Comparative Experimental Biology

Abstract:The keratin cytoskeleton of the wound epidermis of lizard limb (which does not regenerate) and tail (which regenerates) hase been studied by qualitative ultrastructural, immunocytochemical, and immunoblotting methods. The process of re-epithelialization is much shorter in the tail than in the limb. In the latter, a massive tissue destruction of bones, and the shrinkage of the old skin over the stump surface, delay wound closure, maintain inflammation, reduce blastemal cell population, resulting in inhibition of regeneration. The expression of special wound keratins found in the newt epidermis (W6) or mammalian epidermis (K6, K16, and K17) is present in the epidermis of both tail and limb of the lizard. These keratins are not immunolocalized in the migrating epithelium or normal (resting) epidermis but only after it has formed the thick wound epithelium, made of lacunar cells. The latter are proliferating keratinocytes produced during the cyclical renewal or regeneration of lizard epidermis. W6-immunolabeled proteic bands mainly at 45-47 kDa are detected by immunoblotting in normal, regenerating, and scarring epidermis of the tail and limb. Immunolabeled proteic bands at 52, 62-67 kDa (with K6), at 44-47, 60, 65 kDa (with K16), and at 44-47 kDa (with K17) were detected in normal and regenerating epidermis. It is suggested that: (1) these keratins constitute normal epidermis, especially where the lacunar layer is still differentiating; (2) the wound epidermis is similar in the limb and tail in terms of morphology and keratin content; (3) the W6 antigen is similar to that of the newt, and is associated with tonofilaments; (4) lizard K6 and K17 have molecular weights similar to mammalian keratins; (5) K16 shows some isoforms or degradative products with different molecular weight from those of mammals; (6) K17 increases in wound keratinocytes and localizes over sparse filaments or small bundles of short filaments, not over tonofilaments joined to desmosomes; and (7) failure of limb regeneration in lizards may not depend on the wound reaction of keratinocytes.
What's new in the pathogeneses and triggering factors of bullous pemphigoid

Hideyuki Ujiie

DOI: https://doi.org/10.1111/1346-8138.16654

2022-11-24

Abstract:Bullous pemphigoid (BP) is a subepidermal blistering disease induced by autoantibodies to type XVII collagen (COL17, also called BP180) and BP230. Previous studies using patients' samples and animal disease models elucidated the complement‐dependent and complement‐independent pathways of blister formation, the pathogenic roles of immune cells (T and B cells, macrophages, mast cells, neutrophils, eosinophils), and the pathogenicity of IgE autoantibodies in BP. This review introduces the recent progress on the mechanism behind the epitope‐spreading phenomenon in BP, which is considered to be important to understand the chronic and intractable disease course of BP, and the pathogenicity of anti‐BP230 autoantibodies, mainly focusing on studies that used active disease models. To clarify the pathogenesis of BP, the mechanism behind the breakdown of immune tolerance to BP antigens should be investigated. Recent studies using various experimental models have revealed important roles for regulatory T cells in the maintenance of self‐tolerance to COL17 and BP230 as well as in the suppression of inflammation triggered by the binding of antibodies to COL17. Notably, physical stresses such as trauma, thermal burns, bone fractures, irradiation and ultraviolet exposure, some pathologic conditions such as neurological diseases and hematological malignancies, and the use of dipeptidyl peptidase‐IV inhibitors and immune checkpoint inhibitors have been reported as triggering factors for BP. These factors and certain underlying conditions such as genetic background, regulatory T‐cell dysfunction or aging might synergistically affect some individuals and eventually induce BP. Further studies on the breakdown of self‐tolerance and on the identification of key molecules that are relevant to blister formation and inflammation may expand our understanding of BP's etiology and may lead to the development of novel therapeutic approaches.

dermatology
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

Adriana T Lopez,Trisha Khanna,Nina Antonov,Claire Audrey-Bayan,Larisa Geskin

DOI: https://doi.org/10.1111/ijd.13984

Abstract:Background: Dermatologic toxicity represents a substantial portion of all immune-related adverse events (irAEs) associated with PD-1/PD-L1 inhibitors. Bullous pemphigoid (BP) is a rare cutaneous side effect of these medications, which can initially be clinically indistinguishable from other, low-grade cutaneous toxicity. Objective: To better characterize the clinical features of BP associated with PD-1/PD-L1 inhibitors, evaluate the efficacy of various treatment regimens, determine the frequency of prodromal pruritus, and assess whether immunological diagnostic studies for BP are warranted in patients treated with checkpoint inhibitors who develop intractable pruritus. Methods: A comprehensive review of the English-language medical literature was performed using key terms. Papers published on any date and from all origins were considered. Fourteen publications, containing 21 patient cases, were selected independently by two reviewers and deemed relevant to the present publication. Results: Pruritus was a prominent feature of the majority (12/21) of cases and preceded or occurred concurrently with BP development. Bullae developed within 6-8 months of initiation of PD-1/PD-L1 inhibitors; however, a smaller subset of patients did not develop bullae for 1-1.5 years following initiation of therapy. Mean time to pruritus was similar for pembrolizumab and nivolumab at 19 and 21 weeks, respectively. Development of BP required discontinuation of immunotherapy in 76% (16/21) of cases. Conclusion: Prodromal or "non-bullous" variants of BP must be considered in patients treated with checkpoint inhibitors who develop protracted or worsening pruritus. Early diagnostic immunological evaluation of the skin may lead to improved patient outcomes by facilitating timely initiation of treatment and prevent disruptions in cancer therapy.
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid

Fangyuan Chen,Yiman Wang,Xinyi Chen,Nan Yang,Li Li

DOI: https://doi.org/10.1080/07853890.2023.2188487

Abstract:Aim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230. Both immunoglobulin (Ig)G and IgE are involved in the induction of subepidermal blisters. Specifically, IgE autoantibodies are presumed to be responsible for the pruritic and erythematous features of BP. Histologically, eosinophil infiltration is a prominent feature in BP. Eosinophils and IgE are mostly associated with the Th2 immune response. Th2 cytokines, particularly interleukin (IL)-4 and IL-13, are presumed to contribute to the pathology of BP. The aim of this review is to discuss the role of IL-4/13 in the pathogenesis of BP and the potential of using IL-4/13 antagonists for treatment.Methods: After searching in PubMed and Web of Science databases using 'bullous pemphigoid', 'interleukin-4/13', and 'dupilumab' as keywords, studies related was compiled and examined.Results: Overall, IgE, eosinophils, IL-4, and IL-13 may interact with each other in the pathogenesis of BP; these potential interactions provide clues concerning targets for molecular treatment.Conclusion: Anti-IL-4/13 treatment has been experimentally used in patients with BP, with satisfactory outcomes and few side effects. However, before this novel therapy can be approved for regular usage, further studies are needed concerning the long-term safety and systemic usage of IL-4/13 monoclonal antibody treatment in BP.KEY MESSAGESBP is an autoimmune skin disease with Th2-mediated autoimmune response involvement.As typical Th2 cytokines, IL-4 and IL-13 may contribute to the pathogenesis of BP in multiple ways, such as promoting Th2 cell polarization, driving the immunoglobulin class switching, recruiting eosinophils and basophils, and inducing pruritus.As a promising therapeutic approach for BP, IL-4/13 antagonists have shown satisfactory outcomes in preliminary clinical studies.
Meta-analyses and overviews of randomised trials.

S. Richards

DOI: https://doi.org/10.1016/S0268-960X(95)90029-2

IF: 10.626

1995-06-01

Blood Reviews

Abstract:
The "entanglement" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations

Jing-Hui Li,Ya-Gang Zuo

DOI: https://doi.org/10.1080/1744666x.2024.2428621

2024-11-18

Expert Review of Clinical Immunology

Abstract:Introduction Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by subepidermal tense blisters, accompanied by urticarial or eczema-like lesions. Circulating autoantibodies in BP patients target BP180 and BP230 at the dermal-epidermal junction. There has been a growing interest in unraveling the intricate relationship between BP and diabetes mellitus (DM), but a comprehensive review is lacking.

immunology

Currently approved post-exposure rabies prophylaxis regimens.

To Cut is to Cure: The Surgeon's Role in Improving Value

Effect of colostomy on experimentally produced neoplasms of the colon of the rat

Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Malignancies in bullous pemphigoid: A controversial association

Effects of a candidate antifouling compound (medetomidine) on pheromone induced mate search in the amphipod Corophium volutator.

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

The effect of platinum derivatives on interfacial properties of DNA.

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Neurological and psychiatric associations in bullous pemphigoid-more than skin deep?

Prevalence and genotypes of Giardia duodenalis in 1-2 year old dairy cattle.

Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

Intraorbital arteriovenous fistula secondary to penetrating injury.

Wound keratins in the regenerating epidermis of lizard suggest that the wound reaction is similar in the tail and limb.

What's new in the pathogeneses and triggering factors of bullous pemphigoid

A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid

Meta-analyses and overviews of randomised trials.

The "entanglement" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations